Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
...
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days. Clinically relevant reduction in 90-day...
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update. "We are ...
DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of ...
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic...
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2023 and provided a corporate update. "We...
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the...
DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New...
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce,...
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic modulator programs for the treatment of acute organ...
DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms....
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will...
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a corporate...
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference...
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ...
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update....
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the...
Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, and DURECT Corporation...
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO will be presenting virtually at the H.C. Wainwright 24th ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.